Genzyme plant cleanup to take longer than expected

The decontamination of a Boston-area Genzyme plant due to a virus in a bioreactor will take longer than expected, the company says, extending the rationing of the two drugs made there.

The extension is a result of expanding the cleanup. The company says more time is needed so virus-killing vaporized hydrogen peroxide can be dispersed throughout the plant's purification area and the cell-culture area, according to a Boston Globe report. "We've decided to sanitize the entire manufacturing facility, not just the cell-culture production area,'' says Genzyme spokeswoman Lori Gorski, in the Globe.

The plant is used to make Cerezyme and Fabrazyme, enzyme-replacement treatments for Gaucher disease and Fabry disease, respectively, as we reported last week.

Genzyme says it is following a "well-established and proven method" for removing the contaminant, Vesivirus 2117: disassembly and removal of equipment, cleaning, disinfection of cell culture and downstream production suites with vaporous hydrogen peroxide, installation of new air filters and insulation, and other measures. When sanitization is complete, equipment will be reassembled, tested and brought back into operation on a rolling basis. Genzyme says it will not be required to perform process validation runs.

- here's the Boston Globe report
- see the Genzyme announcement

Suggested Articles

AbbVie will soon own Allergan’s prized Botox franchise, and along with its roughly $4 billion in sales, it will get a new $176 million plant.

Merck KGaA has big plans for a site in Switzerland where it intends to knit together biologics development and manufacturing. 

The FDA has found some issues with Biocon’s small molecule plant in Bengaluru, India.